fashion -WSS

fashion

author：focus 2025-09-06 05:03:22 - browse：85

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Duchenne patients, backed by ‘dark money’ group, to debate drug prices

hotspot

WSS

Readout Newsletter: Merck, Vertex, and Viking updates

Steward Health Care has deal to sell doctor network to UnitedHealth

A new study asks: Are we harming blood donors by taking blood?

A new study asks: Are we harming blood donors by taking blood?

There's no autism epidemic. It's an autism diagnosis epidemic

When is a doctor not a doctor? Try when patients address women doctors

leisure time

fashion

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Listen: PBM conflicts, RSV vaccines, & the future of flu season

New air purifier tech could be key to improving indoor air quality

Option Care buys Amedisys in $3.6 billion home care deal

Continuity nursing helped my family in our darkest PICU moments

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Moonlake's readout produced a cash windfall. Risks remain

PhRMA sues HHS over Medicare drug price negotiation

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

hotspot

Eliminate the waiting period for sterilization covered by Medicaid

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Pfizer's Covid pill remains 89% effective in final analysis, company says

There's no autism epidemic. It's an autism diagnosis epidemic

Oprah kicked off a national conversation on obesity. Let's have it

Supreme Court mifepristone arguments center on docs' right to sue

Wikipedia

knowledge

hotspot

leisure time